Willow Biosciences Increases Bought Deal Financing To $25.0 Million
Late last night, Willow Biosciences (TSX: WLLW) announced the upsizing of its bought deal financing following strong demand. The company has seen its financing grow from $20.0 million to that of $25.0 million in gross proceeds that will be raised.
The financing, lead by Eight Capital and BMO Capital Markets, will see a total of 15.2 million shares of the company sold at a price of $1.65 per each, raising gross proceeds of $25.0 million. No warrants are included in the offering, while a 15% over-allotment option has also been granted in connection with the financing.
Proceeds from the financing are to be used for helping access new markets for the firms cannabinoid portfolio, accessing additional manufacturing capacity, expediting the commercialization of new cannabinoids, and working capital and general corporate purposes.
Willow Biosciences last traded at $1.91 on the TSX.
FULL DISCLOSURE: Willow Biosciences Inc is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Willow Biosciences Inc on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
